Cellular Immunology Metabolism Core

摘要 路易斯安那州立大学癌症中心的细胞免疫和代谢核心(CIMC)成立于 2006年，目标是为初级首席调查员提供流式细胞仪支持 在科布雷第一阶段“指导路易斯安那州的翻译研究人员”(MTRL)期间获得资助。 在第二阶段和第三阶段，中集集团不仅为Cobre提供创新技术- 此外，还向LSUHSC调查人员和我们区域的其他用户提供了支持。自2017年以来， CIMC得到了科布雷第一期翻译病毒肿瘤学中心的部分支持 (CTVO)，并被CTVO JPI广泛使用。我们将在第二阶段CTVO中继续提供支持，并 进一步扩展我们为日本邮政总局提供的服务。目前，中集集团的实验室提供全面的分析 流式细胞术和高速细胞分选服务以及包括丝裂原诱导的功能分析 细胞增殖，细胞因子产生，细胞死亡和存活，细胞介导的细胞毒性，效应T细胞 频率，以及通过多种方法检测免疫介质。在第I阶段， CTVO、CIMC将基础设施和专业知识扩展到细胞代谢分析，包括 常氧和低氧条件下的耗氧量、酸化率和线粒体功能 环境。这些额外的CIMC服务现在将支持CTVO第二阶段JPI的需求 至少3个研究项目。这将允许扩展JPI在识别新的 病毒诱发癌症的生物标志物及相关细胞生长和细胞死亡反应的评估 与病毒致癌和肿瘤微环境有关。此外，创新的方法是 在CIMC人员中不断发展，并将提供给JPI及其导师 开发新的实验策略以探索病毒在肿瘤细胞水平上的变化 信号转导和肿瘤细胞能量代谢。这些先进的技术使中集集团 作为该地区领先的癌症和免疫学实验室，导致用户增加， 包括CTVO JPI，以及作为LSUHSC学院核心实验室的CIMC集成 医学，路易斯安那州立大学和杜兰癌症中心共同设在路易斯安那州癌症研究中心 (LCRC)。

ABSTRACT The Cellular Immunology and Metabolism Core (CIMC) of the LSU-Cancer Center was created in 2006 with the objective of providing flow cytometry support to Junior Principal Investigators (JPIs) funded during the Phase I COBRE “Mentoring Translational Researchers in Louisiana” (MTRL). During Phase II and Phase III, CIMC evolved to provide innovative technologies not only to COBRE- supported JPIs, but also to the LSUHSC investigators and to other users in our region. Since 2017, the CIMC has been partially supported by the Phase I COBRE “Center for Translational Viral Oncology (CTVO) and extensively used by CTVO JPIs. We will continue that support In Phase 2 CTVO and further expand our services for JPIs. Current CIMC laboratories, now, provide comprehensive analytic flow cytometry and high-speed cell sorting services and functional assays including mitogen-induced cell proliferation, cytokine production, cell death and survival, cell mediated cytotoxicity, effector T cell frequency, and the detection of immune mediators through multiplex approaches. During Phase I of the CTVO, CIMC expanded infrastructure and expertise to analysis of cellular metabolism, including oxygen consumption and acidification rates, and mitochondrial function in both normoxic and hypoxic environments. These additional CIMC services will now support the needs of CTVO Phase II JPIs in at least 3 Research Projects. This will allow for expansion of JPI expertise in identifying new biomarkers of virus-induced cancers and evaluation of cell growth and cell death responses associated with viral oncogenesis and the tumor microenvironment. In addition, innovative approaches, are continuously evolving in the CIMC personnel, and will be made available to JPIs and their mentors for developing new experimental strategies to explore virus-induced changes at the levels of tumor cell signaling, and tumor cell energy metabolism. These advanced technologies have positioned the CIMC as the leading laboratory in cancer and immunology in the region, resulting in increased users, including CTVO JPIs, as well as CIMC integration as a core laboratory for the LSUHSC School of Medicine, and LSU and Tulane Cancer Centers co-located in the Louisiana Cancer Research Center (LCRC).